Kemiex has secured equity investments from the strategic investment arm of CME Group, CME Ventures, the global data and analytics company DTN, as well as the family office Wille Finance.
Kemiex sees significant impact of the energy crisis in Europe on local feed additive production as well as on active pharmaceutical ingredients (APIs) and other chemicals.
Vitamins B5 and K3 prices are trading at 52-weeks highs, while vitamin E and amino acids, such as lysine and methionine, are trading slightly softer but at higher-than-previous levels.
